Evidence map›Paper›PMID 39380387›Full record

ArticleAdvanced healthcare materials2024

Prodrug Nanomedicine for Synovium Targeted Therapy of Inflammatory Arthritis: Insights from Animal Model and Human Synovial Joint Fluid.

Zeynab Nosrati, Yun An Chen, Marta Bergamo, Cristina Rodríguez-Rodríguez, Jonathan Chan, Kam Shojania, Raheem B Kherani, Carson Chin, John T Kelsall, Natasha Dehghan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zeynab NosratiFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.ORCID 0000-0001-7092-942X
Yun An ChenFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.
Marta BergamoFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.ORCID 0000-0003-3905-0585
Cristina Rodríguez-RodríguezFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.ORCID 0000-0002-3313-4422
Jonathan ChanDepartment of Medicine - Rheumatology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.ORCID 0000-0003-0830-3180
Kam ShojaniaDepartment of Medicine - Rheumatology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.ORCID 0000-0003-2525-3744
Raheem B KheraniDepartment of Medicine - Rheumatology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.ORCID 0000-0001-6833-905X
Carson ChinBurnaby Medical and Surgical Specialists, Burnaby, BC, V3J 1M2, Canada.
John T KelsallDepartment of Medicine - Rheumatology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.
Natasha DehghanPolaris Rheumatology, Vancouver, BC, V5Z 1H2, Canada.
Ann Marie ColwillPolaris Rheumatology, Vancouver, BC, V5Z 1H2, Canada.
David CollinsDepartment of Medicine - Rheumatology, University of British Columbia, 2775 Laurel St, Vancouver, BC, V5Z 1M9, Canada.
Katayoun SaatchiFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.ORCID 0000-0002-5372-6791
Urs O HäfeliFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V5Z 3P2, Canada.ORCID 0000-0003-0671-4509

Funding

Canada Foundation for Innovation 25413Lundbeck Foundation 2014-4176Natural Sciences and Engineering Research Council of CanadaUniversity of British Columbia
6 · The paper itself

Abstract

Many patients cannot tolerate low-dose weekly methotrexate (MTX) therapy for inflammatory arthritis treatment due to life-threatening toxicity. Although biologics offer a target-specific therapy, it raises the risk of serious infections and even cancer due to immune system suppression. We introduce an anti-inflammatory arthritis MTX ester prodrug using a long-circulating biocompatible polymeric macromolecule: folic acid (FA) functionalized hyperbranched polyglycerol (HPG). In vitro the drug MTX is incrementally released through pH and enzymatic degradation over 2 weeks. The role of matrix metalloproteinases (MMPs) in site-specific prodrug activation was verified using synovial fluid (SF) of 26 rheumatology patients and 4 healthy controls. Elevated levels of specific MMPs-markers of joint inflammation-positively correlated with enhanced prodrug release explained by acid-catalyzed hydrolysis of esters by proteases. Intravenously administered

Indexed as

Arthritis, RheumatoidMethotrexateProdrugsSynovial FluidAnimalsDisease Models, AnimalFemaleFolic AcidGlycerolHumansMaleMatrix MetalloproteinasesMiceNanomedicinePolymersSynovial MembraneFolic AcidGlycerolMatrix MetalloproteinasesMethotrexatepolyglycerolPolymersProdrugsdrug delivery systemmethotrexatepolymerprodrugsynovial fluid

Identifiers

PMID39380387
PMCPMC11616258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.